Dr Lal PathLabs, a leading diagnostic and healthcare service provider, has announced its financial results for the quarter ended December 31, 2025, reporting robust growth despite regulatory headwinds.
The company recorded consolidated revenue of Rs 660 crore in Q3 FY26, up 10.6% from Rs. 597 crore in the same quarter last year. For the nine months ended December 2025, revenue grew 10.8% to Rs. 2,060 crore.
EBITDA before exceptional items surged 16.3% to Rs 179 crore, with a margin of 27.2%. The quarter’s profit and loss also reflects an exceptional impact of Rs. 30.1 crore due to new labour codes. PAT stood at Rs. 91 crore, with a margin of 13.9%.
Commenting on the results, the company announced an interim dividend of Rs. 3.5 per share for Q3 FY26, while cash and bank balances reached Rs. 1,411 crore as of December 31, 2025.
A breakdown of the quarter shows -- Material consumed: Rs. 129 crore; Employee benefit expenses: Rs. 135 crore; Fees to collection centres: Rs 96 crore; Other expenses: Rs. 121 crore
After factoring in the statutory labour code impact, EBITDA was Rs. 149 crore, and PBT stood at Rs. 124 crore. EPS for the quarter was Rs. 5.4, compared to Rs. 5.8 in Q3 FY25.
Despite regulatory pressures, the company emphasized steady growth. “Revenue increased by 10.6% in Q3 FY26 and by 10.8% for nine months ended Dec’25,” the company stated, highlighting operational resilience."
Dr Lal PathLabs’ strong cash position and strategic focus position it well for continued growth in India’s healthcare diagnostics sector.
